Mitochondrial Dysfunction Dopaminergic Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitochondrial dysfunction is a central hallmark of Parkinson's disease, particularly affecting dopaminergic neurons in the substantia nigra. These neurons have high energy demands and are uniquely vulnerable to mitochondrial impairment.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
- Reduced NADH dehydrogenase activity
- Impaired electron transport
- Decreased ATP production
- Increased electron leak
- Superoxide radical formation
- Hydrogen peroxide accumulation
- Hydroxyl radical formation
- Oxidative damage to macromolecules
¶ Calcium Handling
- Impaired mitochondrial calcium uptake
- Dysregulated cytosolic calcium
- Excitotoxicity susceptibility
- Reduced buffering capacity
- Swollen mitochondria
- Reduced cristae density
- Mitochondrial DNA deletions
- Membrane potential loss
- Reduced oxygen consumption rate
- Decreased ATP production
- Impaired respiratory control
- Increased vulnerability to toxins
- PINK1 mutations
- PARKIN mutations
- LRRK2 mutations
- Mitochondrial DNA mutations
- MPTP exposure
- Rotenone
- Paraquat
- Chronic rotenone exposure
- Accumulated mtDNA mutations
- Declining mitochondrial function
- Reduced mitophagy
- Telomere attrition
- PGC-1α activators
- AMPK agonists
- Sirt1 activators
- Exercise
- Coenzyme Q10
- MitoQ
- Vitamin E
- N-acetylcysteine
- Mitophagy enhancers
- Mitochondrial fusion proteins
- Autophagy modulators
- Protein degradation pathways
- MPTP-treated neuronal cultures
- Rotenone-exposed dopaminergic cells
- mtDNA-depleted cells (rho0)
- Patient-derived neurons with mtDNA mutations
- MPTP-treated mice
- Rotenone-treated rodents
- Complex I knockout mice
- Transgenic mitochondrial dysfunction models
- Decreased complex I activity in platelets
- Elevated mitochondrial DNA deletions in blood
- Reduced PGC-1α expression in blood cells
- Increased oxidative stress markers
- Mitochondrial complex I restoration
- Antioxidant delivery
- Mitophagy induction
- Energy metabolism support
The study of Mitochondrial Dysfunction Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Schapira et al., Mitochondrial complex I deficiency in Parkinson's disease (1989)
- Winklhofer & Haass, Mitochondrial dysfunction in Parkinson's disease (2010)
- Exner et al., Mitochondrial dysfunction in Parkinson's disease (2012)
- Borsche et al., Mitochondria and Parkinson's Disease (2021)